By Josh Beckerman
Codexis shares rose 31% as the enzyme engineering company entered an exclusive licensing agreement with Roche Holding for its newly engineered double-stranded DNA ligase and its EvoT4 DNA ligase.
The stock was recently at $4.18 on Tuesday and is up about 37% this year.
Codexis said the newly engineered ligase improves the ligation efficiency of DNA fragments and adapters during next-generation sequencing.
The deal, which supersedes a prior exclusive license for EvoT4, includes upfront and technical milestone payments.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
02-27-24 1316ET